Their second study, which demonstrated highly significant predictive value for SAA in RCC metastatic patients treated by tyrosine-kinase inhibitors (TKI), is in agreement with our data, albeit they did not specify the SAA variant.
← all excerpts
Experimental and computational modeling for signature and biomarker discovery of renal cell carcinoma progression.
1
—
—